CHARIOTEER Trademark

Trademark Overview


On Friday, December 12, 2008, a trademark application was filed for CHARIOTEER with the United States Patent and Trademark Office. The USPTO has given the CHARIOTEER trademark a serial number of 79066733. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Tuesday, July 30, 2019. This trademark is owned by ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD. The CHARIOTEER trademark is filed in the Pharmaceutical Products category with the following description:

Antipyretyc, analgesic and anti-inflammatory active pharmaceutical ingredient, namely, naproxen, naproxen sodium, naproxen celecoxib, nimesulide, aceclofenac, sulindac, ibuprofen, fenoprofen, ketoprofen, celecoxib, nimesulide, aceclofenac; anti-inflammatory active pharmaceutical ingredient, namely, naproxen nitroxyalkylesters; antipyretic and analgesic active pharmaceutical ingredient, namely, aspirin, acetaminophen, propyphenazone; antipyretic and analgesic, antithrombotic active pharmaceutical ingredient, namely, indomethacin; analgesic active pharmaceutical ingredient, namely, eptazocine, ketorolac tromethamine; antipyretic, analgesic active pharmaceutical ingredient, namely, propyphenazone; anti-inflammatory and anti-virus active pharmaceutical ingredient, namely, amantadine hydrochloride; treating rheumatoid arthritis active pharmaceutical ingredient, namely, flurbiprofen, meloxicam, phenylbutazone; anti-platelet aggregation active pharmaceutical ingredient, namely, clopidogrel hy...
charioteer

General Information


Serial Number79066733
Word MarkCHARIOTEER
Filing DateFriday, December 12, 2008
Status706 - SECTION 71 ACCEPTED
Status DateTuesday, July 30, 2019
Registration Number3722653
Registration DateTuesday, December 8, 2009
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, September 22, 2009

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of a stylized wheel and axle with two Chinese characters and the wording "CHARIOTEER" appearing beneath the design.
Goods and ServicesAntipyretyc, analgesic and anti-inflammatory active pharmaceutical ingredient, namely, naproxen, naproxen sodium, naproxen celecoxib, nimesulide, aceclofenac, sulindac, ibuprofen, fenoprofen, ketoprofen, celecoxib, nimesulide, aceclofenac; anti-inflammatory active pharmaceutical ingredient, namely, naproxen nitroxyalkylesters; antipyretic and analgesic active pharmaceutical ingredient, namely, aspirin, acetaminophen, propyphenazone; antipyretic and analgesic, antithrombotic active pharmaceutical ingredient, namely, indomethacin; analgesic active pharmaceutical ingredient, namely, eptazocine, ketorolac tromethamine; antipyretic, analgesic active pharmaceutical ingredient, namely, propyphenazone; anti-inflammatory and anti-virus active pharmaceutical ingredient, namely, amantadine hydrochloride; treating rheumatoid arthritis active pharmaceutical ingredient, namely, flurbiprofen, meloxicam, phenylbutazone; anti-platelet aggregation active pharmaceutical ingredient, namely, clopidogrel hydrogen sulfate; anti-platelet drugs active pharmaceutical ingredient, namely, prasugrel; anti-cancer active pharmaceutical ingredient, namely, topotecan hydrochloride, ifosfamide, mesna, irinotecan, camptothecin, 7-ethyl-10-hydrol-camptothecin, docetaxel; treating iodine deficiency active pharmaceutical ingredient, namely, iodine; anti-goitre expectoration and active pharmaceutical ingredient, namely, potassium iodide; treating supraventricular arrhythmia, typical angina and variant angina active pharmaceutical ingredient, namely, diltiazem; anti-hepatitis B virus active pharmaceutical ingredient, namely, adefovir dipivoxil, lamivudine, telbivudine, clevudine; anti-urogenital system disease active pharmaceutical ingredient, namely, phenazopyridine hydrochloride; anti-virus active pharmaceutical ingredient, namely, acyclovir, acyclovir sodium, penciclovir, zidovudine, ganciclovir, ganciclovir sodium, famciclovir, valaciclovir hydrochloride, valganciclovir hydrochloride, ribavirin, 6-deoxyacyclovir, polyinosinic polycytidylic acid, interferons, adenine, farmivisen, docosanol, zanamvir, oseltamivir, indinavir, ritonavir, nelfinavir, delavirdine, efavirenz, ainprenavir, lopinavir, cidofovir, imiquimod, didanosine, foscarnet sodium, penciclovir sodium, stavudine, abacavir, tenofovir disoproxil, emdtricitabine, brivudine, amprenavir, rimantadine; expectorant active pharmaceutical ingredient, namely, fudosteine, carbocisteine; anti-hypertension active pharmaceutical ingredient, namely, valsartan, losartan, irbesartan, tasosartan, candesartan, telmisartan, eprosartan, olmesartan; anxiolytic active pharmaceutical ingredient, namely, brofoxine; treating coronary heart disease active pharmaceutical ingredient, namely, dipyridamole; immunosuppressive active pharmaceutical ingredient, namely, tacrolimus; immunosuppressive agents active pharmaceutical ingredient, namely, sirolimus; treating cardiac and cerebrovascular disease active pharmaceutical ingredient, namely, nicergoline; treating coronary heart disease active pharmaceutical ingredient, namely, isosorbide mononitrate; anti-obesity active pharmaceutical ingredient, namely, orlistat; antipsychotic active pharmaceutical ingredient, namely, perazine maleate, carisoprodol; anti-leprosy disease active pharmaceutical ingredient, namely, thalidomide; anti-vitamin deficiency active pharmaceutical ingredient, namely, folic acid, dexpanthenol; anti-megaloblastic anemia active pharmaceutical ingredient, namely, calcium levofolinate; antithrombotic active pharmaceutical ingredient, namely, ticlopidine hydrochloride; anti-rejection active pharmaceutical ingredient, namely, rapamycin, mizoribine, mycophenolic acid, mycophenolate mofetil, mycophenolate sodium, clarithromycin, daptomycin, mupirocin, ertapenem, doripenem, biapenem, meropenem, imipenem, faropenem, aztreonam, benflumetol, mupirocin, caspofungin; treating diabetes mellitus active pharmaceutical ingredient, namely, metformin, voglibose; antioxidant, treatment heart disease and anti-hypertension active pharmaceutical ingredient, namely, coenzyme Q10; treating brain edema and glaucoma active pharmaceutical ingredient, namely, isosorbide; anti-aids active pharmaceutical ingredient, namely, nevirapine
Transliteration StatementThe non-Latin characters in the mark transliterate to "CHE TOU" and this means "charioteer" and "the front of a vehicle" in English.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 17, 2009
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressTaizhou 310000
CN

Party NameZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCN

Party NameZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.LTD
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCN

Trademark Events


Event DateEvent Description
Tuesday, July 30, 2019NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Tuesday, July 30, 2019REGISTERED-SEC.71 ACCEPTED
Friday, July 26, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 26, 2019TEAS SECTION 71 RECEIVED
Friday, December 28, 2018INTERNATIONAL REGISTRATION RENEWED
Saturday, December 8, 2018COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Thursday, January 15, 2015NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Thursday, January 15, 2015REGISTERED-SEC.71 ACCEPTED
Thursday, January 15, 2015CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, December 11, 2014TEAS SECTION 71 RECEIVED
Thursday, December 11, 2014TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 30, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, April 1, 2010FINAL DISPOSITION NOTICE SENT TO IB
Thursday, April 1, 2010FINAL DISPOSITION PROCESSED
Tuesday, March 9, 2010FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, December 8, 2009REGISTERED-PRINCIPAL REGISTER
Tuesday, September 22, 2009PUBLISHED FOR OPPOSITION
Wednesday, September 2, 2009NOTICE OF PUBLICATION
Tuesday, August 18, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, August 18, 2009ASSIGNED TO LIE
Tuesday, August 11, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 20, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 15, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 15, 2009TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 22, 2009REFUSAL PROCESSED BY IB
Monday, April 27, 2009NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, April 27, 2009REFUSAL PROCESSED BY MPU
Sunday, April 26, 2009NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, April 25, 2009NON-FINAL ACTION WRITTEN
Tuesday, April 21, 2009APPLICATION FILING RECEIPT MAILED
Friday, April 17, 2009ASSIGNED TO EXAMINER
Friday, April 17, 2009NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 16, 2009SN ASSIGNED FOR SECT 66A APPL FROM IB